The study for evaluating the additional effect of tadalafil in patients with the residual lower urinary tract storage symptoms even after treatment with alpha-1-adrenoreceptor antagonists - The study for evaluating the additional effect of tadalafil in patients with the residual storage symptoms even after treatment with alpha-1-adrenoreceptor antagonists

Toranomon Hospital0 个研究点目标入组 100 人开始时间: 2015年7月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients under 50 years old 2. Patients with a history of known serious hypersensitivity reaction to tadalafil, solifenacin succinate or propiverine hydrochloride 3. Patients using nitrates or nitric oxide donors in any form (e.g. nitroglycerin, amyl nitrite or isosorbide dinitrate) 4. Patients using sGC (soluble guanylate cyclase) stimulator (riociguat) 5. Patients with unstable angina 6. Patients with heart failure (NYHA (New York Heart Association) Class 3 or greater) 7. Patients with inadequately controlled arrhythmia, hypotension (blood pressure lower than 90/50 mmHg) or inadequately controlled hypertension (blood pressure at rest higher than 170/100 mmHg) 8. Patients with a history of myocardial infarction within the last 3 months 9. Patients with a history of brain infarction/cerebral hemorrhage within the last 6 months 10. Patients with severe renal impairment 11. Patients with severe hepatic impairment (Child-Pugh Class C) 12. Patients with ischuria 13. Patients with closed angle glaucoma 14. Patients with obstruction in pyrolic part of stomach, duodenal ileus, enterocleisis, or paralytic ileus 15. Patients with gastroatonia/ intestinal atonia 16. Patients with myasthenia gravis 17. Patients with severe cardiac disease 18. Patients with prostate volume more than 50 cc 19. Patients with malignant tumor 20. Patients with a history of intrapelvic surgery

发起方